Breaking News

Charles River Completes Acquisition of Galapagos’ CRO Services

April 1, 2014

Stay tuned for Contract Pharma's Newsmaker interview with CEO, James Foster

Charles River Laboratories (CRL) has completed the acquisition of the CRO services division of Galapagos NV, which includes both Argenta and BioFocus, for$179 million in cash. The acquisition, along with CRL’s current capabilities, adds integrated in vitro and in vivo capabilities from target discovery through preclinical development.
 
Argenta and BioFocus, located in the UK and the Netherlands, provide drug discovery services from target discovery through the delivery of clinic-ready candidates. Their in vitro expertise includes medicinal chemistry, target discovery, and complex in vitro biology, as well as therapeutic area expertise in respiratory, inflammation, oncology, and CNS diseases.
 
The acquisition is expected to add approximately 6% to Charles River’s sales in 2014.
 
For the May issue, be on the look out for Contract Pharma’s Newsmakers piece with Charles River's president and chief executive officer, James C. Foster! 
  • The Human Parts of Mouse Models

    The Human Parts of Mouse Models

    Julia Schueler, Head of in vivo Operations, Oncotest, a Charles River company ||October 11, 2016
    The PDX model system has come back into focus

  • Limiting APIs in Manufacturing Effluent

    Limiting APIs in Manufacturing Effluent

    Joan Tell, Robert Drinane, Bruce Naumann, Jessica Vestel, and Gregory Gagliano, Merck & Co., Inc.||June 2, 2016
    An approach for setting limits on pharmaceuticals discharged in manufacturing effluent

  • Biopharma CMO Market Trends

    Biopharma CMO Market Trends

    Tim Wright, Editor||June 2, 2016
    Continued strong growth in biopharma industry is being driven by biosimilars